Ikena Oncology Inc

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

IMA$3.97-3.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$39,393	$119,894
Marketable securities	84,993	55,571
Prepaid expenses and other current assets	2,783	3,197
Total current assets	127,169	178,662
Property and equipment, net	593	2,335
Right-of-use asset	3,635	5,686
Deposits and other assets	10,113	5,409
Total assets	$141,510	$192,092
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$897	$2,066
Accrued expenses and other current liabilities	6,097	8,581
Operating lease liability	3,784	3,558
Total current liabilities	10,778	14,205
Long-term portion of operating lease liability	3,737	7,180
Other long-term liabilities	1,061	950
Total liabilities	15,576	22,335
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized as of December 31, 2024 and 2023; No shares issued and outstanding as of December 31, 2024 and 2023	—	—
Common stock, $0.001 par value, 150,000,000 shares authorized and 48,258,111 shares issued and outstanding as of December 31, 2024 and 2023	48	48
Additional paid-in capital	457,437	452,142
Accumulated other comprehensive income (loss)	68	(48)
Accumulated deficit	(331,619)	(282,385)
Total stockholders’ equity	125,934	169,757
Total liabilities and stockholders’ equity	$141,510	$192,092

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.